Nishida Toshihiko, Okumura Yasuo, Yokoyama Katsuaki, Matsumoto Naoya, Tachibana Eizo, Kuronuma Keiichiro, Oiwa Koji, Matsumoto Michiaki, Kojima Toshiaki, Hanada Shoji, Nomoto Kazumiki, Sonoda Kazumasa, Arima Ken, Kogawa Rikitake, Takahashi Fumiyuki, Kotani Tomobumi, Ohkubo Kimie, Fukushima Seiji, Itou Satoru, Kondo Kunio, Chiku Masaaki, Ohno Yasumi, Onikura Motoyuki, Hirayama Atsushi
Yokohama Chuo Hospital, Kanagawa, Japan.
Division of Cardiology, Nihon University Itabashi Hospital, Tokyo, Japan.
Heart Vessels. 2019 Dec;34(12):2021-2030. doi: 10.1007/s00380-019-01446-6. Epub 2019 Jun 10.
Direct-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.3%) 75-84 years (elderly) and 264 (8.2%) ≥ 85 years (very elderly) enrolled in a prospective multicenter registry. Kaplan-Meier analysis (median follow-up: 39.3 months) revealed a significantly high incidence of stroke/systemic embolism (SE) among the very elderly relative to that among the non-elderly or elderly (3.2 vs. 1.2 and 1.5 events per 100 patient-years, p < 0.001). Major bleeding in the non-elderly group was significantly infrequent relative to that among the elderly or very elderly group (1.1 vs. 1.6 vs. 1.8 events, p = 0.033). After multivariate adjustment, the stroke/SE incidence was comparable between DOAC and warfarin users, regardless of age, but major bleeding decreased significantly among very elderly DOAC users (adjusted HR 0.220, 95% CI 0.042-0.920). The greater increasing incidence of stroke/SE than major bleeding as patients age suggests that stroke prevention should outweigh the bleeding risk when anticoagulants are being considered for aged patients. Our data indicated that DOACs can be a therapeutic option for stroke prevention in very elderly patients.
直接口服抗凝剂(DOACs)在老年日本房颤(AF)患者中广泛使用,但此类患者的结局数据有限。我们比较了纳入一项前瞻性多中心登记研究的1895例(58.5%)年龄<75岁(非老年)、1078例(33.3%)75 - 84岁(老年)和264例(8.2%)≥85岁(高龄)患者的结局。Kaplan - Meier分析(中位随访时间:39.3个月)显示,高龄患者的卒中/全身性栓塞(SE)发生率显著高于非老年或老年患者(每100患者年3.2次事件 vs. 1.2次和1.5次事件,p<0.001)。非老年组的大出血发生率显著低于老年或高龄组(1.1次事件 vs. 1.6次和1.8次事件,p = 0.033)。多变量调整后,无论年龄如何,DOAC使用者和华法林使用者的卒中/SE发生率相当,但高龄DOAC使用者的大出血显著减少(调整后HR 0.220,95%CI 0.042 - 0.920)。随着患者年龄增长,卒中/SE发生率的增加幅度大于大出血发生率,这表明在考虑为老年患者使用抗凝剂时,预防卒中应优先于出血风险。我们的数据表明,DOACs可作为高龄患者预防卒中的一种治疗选择。